Dextromethorphan provides neuroprotection via anti-inflammatory and anti-excitotoxicity effects in the cortex following traumatic brain injury

Pu,Benfang; Xue,Yonghua; Wang,Qingming; Hua,Chunhui; Li,Xinyuan

doi:10.3892/mmr.2015.3830

Dextromethorphan provides neuroprotection via anti-inflammatory and anti-excitotoxicity effects in the cortex following traumatic brain injury

Authors:
- Benfang Pu
- Yonghua Xue
- Qingming Wang
- Chunhui Hua
- Xinyuan Li
View Affiliations

Affiliations: Department of Neurosurgery, Tongren Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200333, P.R. China
Published online on: May 25, 2015 https://doi.org/10.3892/mmr.2015.3830
Pages: 3704-3710

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Traumatic brain injury (TBI) is caused by primary and secondary injury mechanisms. TBI induces a certain amount of inflammatory responses and glutamate excitotoxicity that are believed to participate in the pathogenesis of secondary injury. The non‑narcotic anti‑tussive drug dextromethorphan (DM) has been reported to have a high safety profile in humans and its neuroprotective against a variety of disorders, including cerebral ischemia, epilepsy and acute brain injury. However, few studies have explored the underlying mechanisms of the neuroprotective effects of DM in animals in the setting of TBI. The aim of the present study was to investigate the neuroprotective effects of DM on TBI and to determine the underlying mechanisms. Rats were subjected to a controlled cortical impact (CCI) injury and randomly divided into three groups: Sham‑operated, TBI and DM treatment groups. The DM treatment group was administered DM (30 mg/kg of body weight, intraperitoneally) immediately after injury. It was identified that DM treatment following TBI significantly reduced brain edema and neurological deficits, as well as increased neuronal survival. These effects correlated with a decrease of tumor necrosis factor α, interleukin‑1β (IL‑1β) and IL‑6 protein expression and an increase of glutamate/aspartate transporter and glutamate transporter‑1 in the cortex of the brain. These results provided in vivo evidence that DM exerts neuroprotective effects via reducing inflammation and excitotoxicity induced following TBI. The present study has shed light on the potential use of DM as a neuroprotective agent in the treatment of cerebral injuries.

View Figures

View References

1	Luo CL, Li BX, Chen XP, et al: Autophagy is involved in traumatic brain injury-induced cell death and contributes to functional outcome deficits in mice. Neuroscience. 184:54–63. 2011. View Article : Google Scholar : PubMed/NCBI
2	Cui C, Cui Y, Gao J, et al: Neuroprotective effect of ceftriaxone in a rat model of traumatic brain injury. Neurol Sci. 35:695–700. 2014. View Article : Google Scholar
3	Morganti-Kossmann MC, Rancan M, Stahel PF and Kossmann T: Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr Opin Crit Care. 8:101–105. 2002. View Article : Google Scholar : PubMed/NCBI
4	Feuerstein GZ, Liu T and Barone FC: Cytokines, inflammation and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev. 6:341–360. 1994.PubMed/NCBI
5	Aibiki M, Maekawa S, Ogura S, Kinoshita Y, Kawai N and Yokono S: Effect of moderate hypothermia on systemic and internal jugular plasma IL-6 levels after traumatic brain injury in humans. J Neurotrauma. 16:225–232. 1999. View Article : Google Scholar : PubMed/NCBI
6	Taupin V, Toulmond S, Serrano A, Benavides J and Zavala F: Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion: Influence of pre-and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand. J Neuroimmunol. 42:177–185. 1993. View Article : Google Scholar : PubMed/NCBI
7	Goodman JC, Robertson CS, Grossman RG and Narayan RK: Elevation of tumor necrosis factor in head injury. J Neuroimmunol. 30:213–217. 1990. View Article : Google Scholar : PubMed/NCBI
8	Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O and Kossmann T: IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-α, TGF-β1 and blood-brain barrier function. J Neuroimmunol. 101:211–221. 1999. View Article : Google Scholar : PubMed/NCBI
9	Hayakata T, Shiozaki T, Tasaki O, et al: Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock. 22:102–107. 2004. View Article : Google Scholar : PubMed/NCBI
10	Lu KT, Wang YW, Yang JT, Yang YL and Chen HI: Effect of interleukin-1 on traumatic brain injury-induced damage to hippocampal neurons. J Neurotrauma. 22:885–895. 2005. View Article : Google Scholar : PubMed/NCBI
11	Globus MY, Alonso O, Dietrich WD, Busto R and Ginsberg MD: Glutamate release and free radical production following brain injury: effects of posttraumatic hypothermia. J Neurochem. 65:1704–1711. 1995. View Article : Google Scholar : PubMed/NCBI
12	Yi JH and Hazell AS: Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int. 48:394–403. 2006. View Article : Google Scholar : PubMed/NCBI
13	Kanai Y and Hediger MA: Primary structure and functional characterization of a high-affinity glutamate transporter. Nature. 360:467–471. 1992. View Article : Google Scholar : PubMed/NCBI
14	Pawlak J, Brito V, Küppers E and Beyer C: Regulation of glutamate transporter GLAST and GLT-1 expression in astrocytes by estrogen. Brain Res Mol Brain Res. 138:1–7. 2005. View Article : Google Scholar : PubMed/NCBI
15	Tanaka K, Watase K, Manabe T, et al: Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science. 276:1699–1702. 1997. View Article : Google Scholar : PubMed/NCBI
16	Tortella FC, Britton P, Williams A, Lu XC and Newman AH: Neuroprotection (focal ischemia) and neurotoxicity (electroen-cephalographic) studies in rats with AHN649, a 3-amino analog of dextromethorphan and low-affinity N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther. 291:399–408. 1999.PubMed/NCBI
17	Werling LL, Lauterbach EC and Calef U: Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist. 13:272–293. 2007. View Article : Google Scholar : PubMed/NCBI
18	Zhang W, Wang T, Qin L, et al: Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J. 18:589–591. 2004.PubMed/NCBI
19	Duhaime AC, Gennarelli LM and Boardman C: Neuroprotection by dextromethorphan in acute experimental subdural hematoma in the rat. J Neurotrauma. 13:79–84. 1996. View Article : Google Scholar : PubMed/NCBI
20	Beni-Adani L, Gozes I, Cohen Y, et al: A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther. 296:57–63. 2001.
21	Povlishock JT, Hayes RL, Michel ME and Mcintosh TK: Workshop on animal models of traumatic brain injury. J Neurotrauma. 11:723–732. 1994. View Article : Google Scholar : PubMed/NCBI
22	Wang CX and Shuaib A: Involvement of inflammatory cytokines in central nervous system injury. Prog Neurobiol. 67:161–172. 2002. View Article : Google Scholar : PubMed/NCBI
23	Allan SM and Rothwell NJ: Cytokines and acute neurodegeneration. Nat Rev Neurosci. 2:734–744. 2001. View Article : Google Scholar : PubMed/NCBI
24	Liu Y, Qin L, Li G, et al: Dextromethorphan protects dopa-minergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther. 305:212–218. 2003. View Article : Google Scholar : PubMed/NCBI
25	Gao HM, Liu B, Zhang W and Hong JS: Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci. 24:395–401. 2003. View Article : Google Scholar : PubMed/NCBI
26	Tortella FC, Pellicano M and Bowery NG: Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci. 10:501–507. 1989. View Article : Google Scholar : PubMed/NCBI
27	Klette KL, Lin Y, Clapp LE, DeCoster MA, Moreton J and Tortella FC: Neuroprotective sigma ligands attenuate NMDA and trans-ACPD-induced calcium signaling in rat primary neurons. Brain Res. 756:231–240. 1997. View Article : Google Scholar : PubMed/NCBI
28	Carpenter CL, Marks SS, Watson DL and Greenberg DA: Dextromethorphan and dextrorphan as calcium channel antagonists. Brain Res. 439:372–375. 1988. View Article : Google Scholar : PubMed/NCBI
29	Feng S, Xu Z, Liu W, Li Y, Deng Y and Xu B: Preventive effects of dextromethorphan on methylmercury-induced glutamate dyshomeostasis and oxidative damage in rat cerebral cortex. Biol Trace Elem Res. 159:332–345. 2014. View Article : Google Scholar : PubMed/NCBI